A scoping document explaining the review process to evaluate existing treatment options for non-small cell lung cancer (NSCLC) has been released by the Institute for Clinical and Economic Review (ICER).
A scoping document explaining the review process to evaluate existing treatment options for non-small cell lung cancer (NSCLC) has been released by the Institute for Clinical and Economic Review, or ICER. The report, which will be reviewed by a Midwest Comparative Effectiveness Public Advisory Council (CEPAC) in September of this year, will evaluate clinical and economic outcomes of tyrosine kinase inhibitors (TKIs) and programmed death 1 (PD-1) agents used to treat NSCLC with a mutated epidermal growth factor receptor (EGFR+). Additionally, PD-1 agents will be valued in NSCLC without a driver mutation.
As with its previous analyses, evidence used will be from clinical trial findings, reviews, and comparative cohort studies if necessary. This information will be supplemented with conference proceedings, regulatory documents, and data submitted by manufacturers.
Researchers at ICER plan to focus on 4 populations of patients with NSCLC, in inpatient, outpatient and clinical settings:
The interventions that will be included in the evaluation are:
The following clinical outcomes will be evaluated:
A simulation model will simultaneously be developed to assess lifetime effectiveness of regimens compared with the standard treatments, especially the first- and second-line regimens. Costs will encompass those for current and subsequent treatments, AE management, and any associated care; quality-adjusted life year (QALY) gained will be the output of the analysis. Additionally, similar to earlier reports, ICER will also provide an estimate of the 5-year budgetary impact of each regimen.
The scoping document can be found here.